Incyte posts Phase 3 STOP-HS2 results for povorcitinib; registers INCB161734 Phase 1 studyNov 6Weekly roundup, 2 itemsINCB161734Incyte CorporationUpdated
Wave Life Sciences details Q3 2026 progress on WVE-006, WVE-007, WVE-008 pipelineOct 28Quarterly updateBristol Myers SquibbEli LillyUpdated
Incyte raises 2026 sales guidance, adds ten data readouts, closes Vega dealJul 28Quarterly updateIncyte Corporation